Search Within
Applied Filters:
Showing 1-11 of 11 results for "


" within Papers
IL-6 in autoimmune disease and chronic inflammatory proliferative disease
Ishihara K and Hirano T
Cytokine & Growth Factor Reviews, 13(4-5), 357-368 (2002)
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
Voorhees PM, et al.
British Journal of Haematology, 161(3), 357-366 (2013)
Peter M Voorhees et al.
British journal of haematology, 161(3), 357-366 (2013-02-26)
Interleukin-6 (IL6) plays a central role in multiple myeloma pathogenesis and confers resistance to corticosteroid-induced apoptosis. We therefore evaluated the efficacy and safety of siltuximab, an anti-IL6 monoclonal antibody, alone and in combination with dexamethasone, for patients with relapsed or...
L M Biasucci et al.
Circulation, 94(5), 874-877 (1996-09-01)
Elevated plasma levels of C-reactive protein have been found in the majority of patients with unstable angina. The evidence of elevated levels of acute-phase proteins in unstable angina is in line with a growing body of evidence that suggests that...
Hidemitsu Kitamura et al.
Immunity, 23(5), 491-502 (2005-11-16)
We found IL-6-STAT3 pathway suppresses MHC class II (MHCII) expression on dendritic cells (DCs) and attenuates T cell activation. Here, we showed that IL-6-STAT3 signaling reduced intracellular MHCII alphabeta dimmer, Ii, and H2-DM levels in DCs. IL-6-mediated STAT3 activation decreased...
Mehmet Kocoglu et al.
Pharmaceuticals (Basel, Switzerland), 9(1) (2016-01-20)
Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has changed considerably over the last two decades with the introduction to the clinical practice of novel agents such as proteasome inhibitors and immunomodulatory drugs. Basic...
L M Biasucci et al.
Circulation, 99(16), 2079-2084 (1999-04-27)
A growing body of evidence suggests a role for inflammation in acute coronary syndromes. The aim of this study was to assess the role of proinflammatory cytokines, their time course, and their association with prognosis in unstable angina. We studied...
H C van Zaanen et al.
The Journal of clinical investigation, 98(6), 1441-1448 (1996-09-15)
In vitro as well as in vivo observations have shown that IL6 plays a key role in the pathogenesis of multiple myeloma. Therefore we started a phase I/II dose escalating study with chimeric monoclonal anti-IL6 antibodies (cMab) in multiple myeloma...
Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines.
Ehrin J Armstrong et al.
Circulation, 113(6), e72-e75 (2006-02-16)
Luca Semerano et al.
Expert opinion on investigational drugs, 23(7), 979-999 (2014-04-29)
IL-6 is a key cytokine in the pathogenesis of rheumatoid arthritis (RA). The clinical efficacy of tocilizumab (TCZ), a humanized anti-IL6-receptor mAb, confirmed the value of IL-6 blockade in this disease. A number of new anti-IL-6 biologics are currently in...
P M Ridker et al.
The New England journal of medicine, 336(14), 973-979 (1997-04-03)
Inflammation may be important in the pathogenesis of atherothrombosis. We studied whether inflammation increases the risk of a first thrombotic event and whether treatment with aspirin decreases the risk. We measured plasma C-reactive protein, a marker for systemic inflammation, in...